Terms: = Kidney tumors AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130
23 results:
1. PROM1-mediated cell signal transduction in cancer stem cells and hepatocytes.
Bahn MS; Ko YG
BMB Rep; 2023 Feb; 56(2):65-70. PubMed ID: 36617467
[TBL] [Abstract] [Full Text] [Related]
2. The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma.
Gudbrandsdottir G; Aarstad HH; Hjelle KM; Førde K; Reisæter L; Bostad L; Aarstad HJ; Beisland C
Cytokine; 2021 Aug; 144():155586. PubMed ID: 34058568
[TBL] [Abstract] [Full Text] [Related]
3. Down-regulation of gp130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis.
He S; Li G; Schätzlein AG; Humphrey PA; Weiss RM; Uchegbu IF; Martin DT
Cell Signal; 2021 May; 81():109931. PubMed ID: 33529758
[TBL] [Abstract] [Full Text] [Related]
4. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).
Gudbrandsdottir G; Aarstad HH; Bostad L; Hjelle KM; Aarstad HJ; Bruserud Ø; Tvedt THA; Beisland C
Cancer Immunol Immunother; 2021 Jan; 70(1):19-30. PubMed ID: 32621022
[TBL] [Abstract] [Full Text] [Related]
5. Partial Nephrectomy for Nephroblastoma: A National Cancer Data Base Review.
Richards MK; Goldin AB; Ehrlich PF; Beierle EA; Doski JJ; Goldfarb M; Langer M; Nuchtern JG; Vasudevan S; Gow KW
Am Surg; 2018 Mar; 84(3):338-343. PubMed ID: 29559046
[TBL] [Abstract] [Full Text] [Related]
6. PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway.
Wang H; Qu Y; Dai B; Zhu Y; Shi G; Zhu Y; Shen Y; Zhang H; Ye D
PLoS One; 2017; 12(8):e0180862. PubMed ID: 28846693
[TBL] [Abstract] [Full Text] [Related]
7. Interleukin-6 as an emerging regulator of renal cell cancer.
Kamińska K; Czarnecka AM; Escudier B; Lian F; Szczylik C
Urol Oncol; 2015 Nov; 33(11):476-85. PubMed ID: 26296264
[TBL] [Abstract] [Full Text] [Related]
8. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
[TBL] [Abstract] [Full Text] [Related]
9. gp130 activation induces myeloma and collaborates with MYC.
Dechow T; Steidle S; Götze KS; Rudelius M; Behnke K; Pechloff K; Kratzat S; Bullinger L; Fend F; Soberon V; Mitova N; Li Z; Thaler M; Bauer J; Pietschmann E; Albers C; Grundler R; Schmidt-Supprian M; Ruland J; Peschel C; Duyster J; Rose-John S; Bassermann F; Keller U
J Clin Invest; 2014 Dec; 124(12):5263-74. PubMed ID: 25384216
[TBL] [Abstract] [Full Text] [Related]
10. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
[TBL] [Abstract] [Full Text] [Related]
11. IL-6 as an intracrine growth factor for renal carcinoma cell lines.
Alberti L; Thomachot MC; Bachelot T; Menetrier-Caux C; Puisieux I; Blay JY
Int J Cancer; 2004 Sep; 111(5):653-61. PubMed ID: 15252833
[TBL] [Abstract] [Full Text] [Related]
12. Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases.
Yano Y; Hayashi Y; Sano K; Nagano H; Nakaji M; Seo Y; Ninomiya T; Yoon S; Yokozaki H; Kasuga M
Cancer Lett; 2004 Apr; 207(2):139-47. PubMed ID: 15072822
[TBL] [Abstract] [Full Text] [Related]
13. Opposing effects of PML and PML/RAR alpha on STAT3 activity.
Kawasaki A; Matsumura I; Kataoka Y; Takigawa E; Nakajima K; Kanakura Y
Blood; 2003 May; 101(9):3668-73. PubMed ID: 12506013
[TBL] [Abstract] [Full Text] [Related]
14. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P.
Horiguchi A; Oya M; Marumo K; Murai M
Kidney Int; 2002 Mar; 61(3):926-38. PubMed ID: 11849447
[TBL] [Abstract] [Full Text] [Related]
15. [Studies on the interaction between interleukin-6 and human renal cell carcinoma cell line GRC-1].
Xi Z; Yu L; Guo Y
Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):308-11. PubMed ID: 11798778
[TBL] [Abstract] [Full Text] [Related]
16. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.
Menetrier-Caux C; Thomachot MC; Alberti L; Montmain G; Blay JY
Cancer Res; 2001 Apr; 61(7):3096-104. PubMed ID: 11306493
[TBL] [Abstract] [Full Text] [Related]
17. Expression of the interleukin 6 receptor in primary renal cell carcinoma.
Costes V; Liautard J; Picot MC; Robert M; Lequeux N; Brochier J; Baldet P; Rossi JF
J Clin Pathol; 1997 Oct; 50(10):835-40. PubMed ID: 9462266
[TBL] [Abstract] [Full Text] [Related]
18. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598.
Koshelnick Y; Ehart M; Hufnagl P; Heinrich PC; Binder BR
J Biol Chem; 1997 Nov; 272(45):28563-7. PubMed ID: 9353320
[TBL] [Abstract] [Full Text] [Related]
19. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract] [Full Text] [Related]
20. Cytokine receptor expression by solid tumours.
Ridings J; Macardle PJ; Byard RW; Skinner J; Zola H
Ther Immunol; 1995 Apr; 2(2):67-76. PubMed ID: 8729878
[TBL] [Abstract] [Full Text] [Related]
[Next]
